
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity is well-positioned to capitalize on the growing demand for advanced research tools and diagnostics, and its strategic acquisitions have diversified its portfolio. The signals software segment also provides a unique opportunity for growth, with its AI-enabled drug discovery platform and potential collaborations with biotech and pharma companies. Revvity's financial strength, coupled with its strong product portfolio and potential for growth, make it a promising investment opportunity for shareholders.
Bears say
Revvity is facing headwinds from a decline in birth rates and expected tough comps for its reproductive health business. The recent weakening in pharmaceutical and biotech spending is also impacting its bottom line and its software segment is facing newfound competition. Despite management's optimistic outlook, organic growth and margin targets are falling short, and the upcoming divestiture of the China immunodiagnostics business raises concerns about future growth potential.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares